These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 3339116)
1. Estrogen-induced prolactinoma in a man. Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116 [TBL] [Abstract][Full Text] [Related]
2. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788 [TBL] [Abstract][Full Text] [Related]
3. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual. García-Malpartida K; Martín-Gorgojo A; Rocha M; Gómez-Balaguer M; Hernández-Mijares A Fertil Steril; 2010 Aug; 94(3):1097.e13-5. PubMed ID: 20227072 [TBL] [Abstract][Full Text] [Related]
4. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine. Osamura RY; Watanabe K Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530 [TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules. Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323 [TBL] [Abstract][Full Text] [Related]
7. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas. Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437 [TBL] [Abstract][Full Text] [Related]
9. Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction. Gooren LJ; Harmsen-Louman W; van Kessel H Clin Endocrinol (Oxf); 1985 Feb; 22(2):201-7. PubMed ID: 3157511 [TBL] [Abstract][Full Text] [Related]
10. [Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis]. Saitoh Y; Koizumi K; Arita N; Hayakawa T; Aono T; Matsumoto K; Mogami H; Mori H No To Shinkei; 1987 Apr; 39(4):347-54. PubMed ID: 3593602 [TBL] [Abstract][Full Text] [Related]
11. Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Asscheman H; Gooren LJ; Assies J; Smits JP; de Slegte R Clin Endocrinol (Oxf); 1988 Jun; 28(6):583-8. PubMed ID: 2978262 [TBL] [Abstract][Full Text] [Related]
12. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. Gillam MP; Middler S; Freed DJ; Molitch ME J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416 [TBL] [Abstract][Full Text] [Related]
13. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease. Peillon F; Dupuy M; Li JY; Kujas M; Vincens M; Mowszowicz I; Derome P J Clin Endocrinol Metab; 1991 Nov; 73(5):1008-15. PubMed ID: 1939514 [TBL] [Abstract][Full Text] [Related]
14. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. Wiedemann E; Schwartz E; Frantz AG J Clin Endocrinol Metab; 1976 May; 42(5):942-52. PubMed ID: 178687 [TBL] [Abstract][Full Text] [Related]
15. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. Prior JC; Cox TA; Fairholm D; Kostashuk E; Nugent R J Clin Endocrinol Metab; 1987 Feb; 64(2):391-4. PubMed ID: 3793856 [TBL] [Abstract][Full Text] [Related]
16. Dihydroergocriptine in management of microprolactinomas. Faglia G; Conti A; Muratori M; Togni E; Travaglini P; Zanotti A; Mailland F J Clin Endocrinol Metab; 1987 Oct; 65(4):779-84. PubMed ID: 3116032 [TBL] [Abstract][Full Text] [Related]
17. [Inhibitory effects of melatonin on the development of 17-beta-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents]. Gao L; Xu JP; Shan HM; Zhang R; Xu RK Sheng Li Xue Bao; 2001 Jun; 53(3):165-9. PubMed ID: 12589398 [TBL] [Abstract][Full Text] [Related]
18. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. Lamberts SW; Verleun T; Hofland L; Oosterom R J Clin Endocrinol Metab; 1986 Dec; 63(6):1342-7. PubMed ID: 3782422 [TBL] [Abstract][Full Text] [Related]
19. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy. Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065 [TBL] [Abstract][Full Text] [Related]
20. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]